Pheochromocytoma: recommendations for clinical practice from the First International Symposium

[1]  A. Arnold,et al.  Review: Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes? , 2006, The Journal of clinical endocrinology and metabolism.

[2]  Marta Barontini,et al.  Characteristics of Pheochromocytoma in a 4‐ to 20‐Year‐Old Population , 2006, Annals of the New York Academy of Sciences.

[3]  K. Byth,et al.  Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. , 2006, The Journal of clinical endocrinology and metabolism.

[4]  W. Young,et al.  Paraganglioma—All in the Family , 2006 .

[5]  Paul Kinahan,et al.  Fluorodeoxyglucose Positron Emission Tomography Improve Clinical Decision Making in Suspected Pheochromocytoma , 2006 .

[6]  J. Carrasquillo,et al.  Discordant localization of 2-[18F]-fluoro-2-deoxy-D-glucose in 6-[18F]-fluorodopamine- and [123I]-metaiodobenzylguanidine-negative metastatic pheochromocytoma sites , 2006, Nuclear medicine communications.

[7]  E. DeLong,et al.  Detecting Pheochromocytoma: Defining the Most Sensitive Test , 2006, Annals of surgery.

[8]  S. Richard,et al.  Genetic testing in pheochromocytoma or functional paraganglioma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  B. Hitt,et al.  Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma. , 2005, Endocrine-related cancer.

[10]  H. Neumann,et al.  Laparoscopic adrenal surgery for recurrent tumours in patients with hereditary phaeochromocytoma. , 2005, European urology.

[11]  C. Larsson,et al.  Pheochromocytoma and functional paraganglioma syndrome: No longer the 10% tumor , 2005, Journal of surgical oncology.

[12]  David I. Smith,et al.  Malignant pheochromocytoma: current status and initiatives for future progress. , 2004, Endocrine-related cancer.

[13]  R. Hinze,et al.  CGH and CD 44/MIB-1 immunohistochemistry are helpful to distinguish metastasized from nonmetastasized sporadic pheochromocytomas , 2004, Modern Pathology.

[14]  Jeffrey E. Lee,et al.  Surgical management of hereditary pheochromocytoma. , 2004, Journal of the American College of Surgeons.

[15]  K. Schmid,et al.  Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass. , 2004, European journal of endocrinology.

[16]  D. O'Kane,et al.  Measurement of plasma free metanephrine and normetanephrine by liquid chromatography-tandem mass spectrometry for diagnosis of pheochromocytoma. , 2004, Clinical chemistry.

[17]  H. Engler,et al.  Pheochromocytomas: detection with 11C hydroxyephedrine PET. , 2004, Radiology.

[18]  I. Ilias,et al.  Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. , 2004, The Journal of clinical endocrinology and metabolism.

[19]  R. Coleman,et al.  Iodine -131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. , 2003, Surgery.

[20]  D. Evans,et al.  Genetic analysis of mitochondrial complex II subunits SDHD, SDHB and SDHC in paraganglioma and phaeochromocytoma susceptibility , 2003, Clinical endocrinology.

[21]  P. Rustin,et al.  Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. , 2003, Cancer research.

[22]  K. Nathanson,et al.  Pheochromocytoma: the expanding genetic differential diagnosis. , 2003, Journal of the National Cancer Institute.

[23]  E. Bravo,et al.  Pheochromocytoma: state-of-the-art and future prospects. , 2003, Endocrine reviews.

[24]  J. Norton,et al.  High‐dose 131I‐metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma , 2003, Cancer.

[25]  M. Walther,et al.  Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. , 2003, The Journal of clinical endocrinology and metabolism.

[26]  R. Lloyd,et al.  Recommendations for the reporting of extra-adrenal paragangliomas. The Association of Directors of Anatomic and Surgical Pathology. , 2003, Human pathology.

[27]  W. Young,et al.  A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. , 2003, The Journal of clinical endocrinology and metabolism.

[28]  J. Strauchen.  Germ-line mutations in nonsyndromic pheochromocytoma. , 2002, The New England journal of medicine.

[29]  T. Lairmore,et al.  Adrenalectomy for Familial Pheochromocytoma in the Laparoscopic Era , 2002, Annals of surgery.

[30]  L. Thompson.  Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) to Separate Benign From Malignant Neoplasms: A Clinicopathologic and Immunophenotypic Study of 100 Cases , 2002, The American journal of surgical pathology.

[31]  M. Walther,et al.  Biochemical diagnosis of pheochromocytoma: which test is best? , 2002, JAMA.

[32]  W. Rubinstein,et al.  Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas , 2002, Journal of medical genetics.

[33]  Ravinder J. Singh,et al.  Validation of liquid chromatography-tandem mass spectrometry method for analysis of urinary conjugated metanephrine and normetanephrine for screening of pheochromocytoma. , 2002, Clinical chemistry.

[34]  D. Crockett,et al.  Rapid analysis of metanephrine and normetanephrine in urine by gas chromatography-mass spectrometry. , 2002, Clinical chemistry.

[35]  H. Neumann,et al.  Pheochromocytomas: detection with 18F DOPA whole body PET--initial results.. , 2002, Radiology.

[36]  K E Britton,et al.  Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with 131I‐meta‐iodobenzylguanidine (131I‐mIBG) , 2001, Clinical endocrinology.

[37]  E S Husebye,et al.  Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. , 2001, American journal of human genetics.

[38]  Graeme Eisenhofer,et al.  6-[18F]Fluorodopamine Positron Emission Tomographic (PET) Scanning for Diagnostic Localization of Pheochromocytoma , 2001, Hypertension.

[39]  D. Ducassou,et al.  Lessons from an unpleasant surprise: a biochemical strategy for the diagnosis of pheochromocytoma , 2001, Journal of hypertension.

[40]  D. Evans,et al.  Germline SDHD mutation in familial phaeochromocytoma , 2001, The Lancet.

[41]  W. Linehan,et al.  Recent Advances in Genetics, Diagnosis, Localization, and Treatment of Pheochromocytoma , 2001, Annals of Internal Medicine.

[42]  E. Chan,et al.  High-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometric method for the analysis of catecholamines and metanephrines in human urine. , 2000, Rapid communications in mass spectrometry : RCM.

[43]  M. Roden,et al.  Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma. , 2000, Archives of internal medicine.

[44]  C. Prys‐roberts.  Phaeochromocytoma--recent progress in its management. , 2000, British journal of anaesthesia.

[45]  B. Devlin,et al.  Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. , 2000, Science.

[46]  F. Askin,et al.  Recommendations for reporting of tumors of the adrenal cortex and medulla. Association of Directors of Anatomic and Surgical Pathology. , 1999, American journal of clinical pathology.

[47]  Lack Ee.  Recommendations for reporting of tumors of the adrenal cortex and medulla. Association of Directors of Anatomic and Surgical Pathology. , 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[48]  I. Francis,et al.  Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-D-glucose PET. , 1999, Radiology.

[49]  W. Linehan,et al.  Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. , 1999, The New England journal of medicine.

[50]  N. Abumrad,et al.  Clinical experience over 48 years with pheochromocytoma. , 1999, Annals of surgery.

[51]  Shin Suzuki,et al.  Malignant pheochromocytoma with multiple hepatic metastases treated by chemotherapy and transcatheter arterial embolization. , 1999, Internal medicine.

[52]  D. Hauri,et al.  Pheochromocytomas: can malignant potential be predicted? , 1999, Urology.

[53]  H. Kiyota,et al.  Diagnosis of pheochromocytoma using [123I]‐ compared with [131I]‐metaiodobenzylguanidine scintigraphy , 1999, International journal of urology : official journal of the Japanese Urological Association.

[54]  G. Bartsch,et al.  Laparoscopic surgery for pheochromocytoma: adrenalectomy, partial resection, excision of paragangliomas. , 1998, The Journal of urology.

[55]  K. Matthay,et al.  The treatment of malignant pheochromocytoma with Iodine-131 metaiodobenzylguanidine (131I-MIBG): A comprehensive review of 116 reported patients , 1997, Journal of endocrinological investigation.

[56]  G. Chatellier,et al.  Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. , 1997, Hypertension.

[57]  W. Young.  Pheochromocytoma: issues in diagnosis & treatment. , 1997, Comprehensive therapy.

[58]  Jeffrey E. Lee,et al.  Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma. , 1996, Surgery.

[59]  J. Carney,et al.  Clinical Spectrum and Outcome of Functional Extraadrenal Paraganglioma , 1996, World Journal of Surgery.

[60]  J. Gnarra,et al.  Loss of heterozygosity on the short arm of chromosome 3 in sporadic, von hippel‐lindau disease‐associated, and familial pheochromocytoma , 1995, Genes, chromosomes & cancer.

[61]  M. Vix,et al.  “The” pheochromocytoma: A benign, intra-adrenal, hypertensive, sporadic unilateral tumor. Does it exist? , 1994, World Journal of Surgery.

[62]  E. Gerlo,et al.  Urinary and plasma catecholamines and urinary catecholamine metabolites in pheochromocytoma: diagnostic value in 19 cases. , 1994, Clinical chemistry.

[63]  B. Ponder,et al.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A , 1993, Nature.

[64]  D. Kuhl,et al.  PET scanning with hydroxyephedrine: an approach to the localization of pheochromocytoma. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[65]  Thomas G Rosano,et al.  Advances in catecholamine and metabolite measurements for diagnosis of pheochromocytoma. , 1991, Clinical chemistry.

[66]  N. Morton,et al.  Von Hippel-Lindau disease: a genetic study. , 1991, Journal of medical genetics.

[67]  S. Steinberg,et al.  Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. , 1990, Human pathology.

[68]  D. Thévenin,et al.  Exclusive use of calcium channel blockers in preoperative and intraoperative control of pheochromocytomas: hemodynamics and free catecholamine assays in ten consecutive patients. , 1989, Surgery.

[69]  E. Gelmann,et al.  Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. , 1988, Annals of internal medicine.

[70]  A H Tashjian,et al.  The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18-year experience. , 1988, The New England journal of medicine.

[71]  R W Gifford,et al.  Circulating and urinary catecholamines in pheochromocytoma. Diagnostic and pathophysiologic implications. , 1979, The New England journal of medicine.

[72]  Z. Górko,et al.  [Extra-adrenal pheochromocytoma]. , 1966, Polski tygodnik lekarski.

[73]  N. Kimura,et al.  Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: A clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors , 2005, Endocrine pathology.

[74]  O. Haas,et al.  Long-term follow up of a “sporadic” unilateral pheochromocytoma revealing multiple endocrine neoplasia MEN2A-2 in an elderly woman , 2003, Endocrine pathology.

[75]  D. Goldstein,et al.  Pheochromocytoma: Rediscovery as a catecholamine-metabolizing tumor , 2003, Endocrine pathology.

[76]  M. Warner,et al.  Perioperative management of pheochromocytoma. , 2002, Journal of cardiothoracic and vascular anesthesia.

[77]  A. Vortmeyer,et al.  Pheochromocytoma in von hippel-lindau disease: Distinct histopathologic phenotype compared to pheochromocytoma in multiple endocrine neoplasia type 2 , 2002, Endocrine pathology.

[78]  H. Bonjer,et al.  [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas. , 2001, The Journal of clinical endocrinology and metabolism.